Key Drivers
- Strong Liquidity
- Deep Losses
- Rising Leverage
AIAI Summary
DRTS is a catalyst-driven bet on Alpha DaRT clinical validation—not a commercial oncology business—where reproducible glioblastoma and head-and-neck efficacy could justify major upside, but its $1.25B valuation, accelerating cash burn, and likely dilution leave little margin for weak or delayed data.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Deep Losses
- •Rising Leverage
DRTS has strong liquidity but severe losses, no revenue, rising interest costs, eroding equity, and an elevated valuation create significant financial risk.
Price Behavior
Key Price Behavior Insights:
- •Modest uptrend
- •Resistance rejection
- •Key support
DRTS shows a modest bullish trend over the last month, with support at $14.27–$14.40 and a breakout above $15.49 needed to strengthen momentum.
Pulled back from the recent $15.49 high, signaling near-term selling pressure
Sentiment & News
Key News Insights:
- •Pancreatic Enrollment Complete
- •Glioblastoma Data Pending
- •Investor Interest Rising
Alpha Tau's completed pancreatic trial enrollment and upcoming glioblastoma readout strengthen its clinical momentum, though execution and regulatory risks remain.
Near-term glioblastoma results could be a key catalyst for Alpha Tau shares, while pancreatic data remains a longer-term driver
Similar Companies in Healthcare
Other companies in the same sector with AI ratings